Semaglutide in Pakistan: 30-Week Data

A prospective study from specialist clinics in Pakistan followed adults with type 2 diabetes who started biosynthetic semaglutide during routine outpatient care. Among 217 people still receiving treatment at the end of 30 weeks, mean HbA1c fell from 9.27% to 7.41%, a 1.86 percentage-point reduction. Mean body weight fell by 7.84 kg, and 76.5% of this end-of-study group lost at least 5% of their starting weight^[1]. These results describe an association in a single-arm observational study. They do not prove that semaglutide alone caused every change.

How the semaglutide study was run

The researchers designed a prospective, multicentre, non-interventional study. Adults had to be at least 18 years old and have a type 2 diabetes diagnosis for at least 12 weeks. They also needed a documented HbA1c result from the 12 weeks before treatment began. Semaglutide was prescribed as part of routine diabetes management rather than assigned randomly by the researchers. The primary endpoint was the change in HbA1c, a measure of average blood glucose over the preceding two to three months. Secondary outcomes covered weight and waist circumference. The team separately tracked treatment satisfaction, quality of life, retention, and adverse events^[2]. The study used commercially available prefilled syringe devices at 0.25 mg, 0.5 mg, or 1.0 mg once weekly. Treating clinicians could maintain or adjust the dose based on response and tolerability. Other glucose-lowering treatment and lifestyle changes were allowed. Visits followed local practice, with an interim assessment between weeks 12 and 18 and a planned final visit at week 30. That flexibility resembles routine care. It also adds factors that a single-arm study cannot separate from the medicine's effect^[2].

A total of 268 participants completed the baseline assessment and entered the full analysis set. By the end, 221 had completed the study, 34 had discontinued treatment, and 13 had an unknown treatment status. Of the completers, 217 were still receiving semaglutide and had the measurements used for the main effectiveness analysis^[2]. The authors also ran an intention-to-treat analysis using the last recorded observation for missing end-of-study data. That method keeps all 268 baseline participants in the analysis, but it assumes an earlier observation is a reasonable stand-in for a missing later one.

Glucose and weight findings at 30 weeks

In the 217-person end-of-study group, 76.6% finished with HbA1c below 8.0%, while 38.7% finished below 7.0%. The mean 7.84 kg weight reduction was accompanied by lower mean body mass index and waist circumference. Treatment satisfaction and the physical component of the quality-of-life measure also improved^[1]. The study was not designed to compare biosynthetic semaglutide against another GLP-1 medicine, insulin, or usual care. That comparison remains unanswered.

The findings are relevant because much of the published semaglutide evidence comes from randomized trials or health systems outside lower- and middle-income settings. This study records what happened in routine specialist care where patients faced out-of-pocket costs. It should still be read as a local cohort, not as an estimate for every person with type 2 diabetes. Our semaglutide research overview places observational findings beside randomized evidence rather than treating the designs as interchangeable.

Safety and treatment retention

The paper reports that adverse events were mainly non-serious and gastrointestinal, and that no severe hypoglycaemic episodes occurred^[1]. Safety reporting was descriptive. Without a concurrent control group, the study cannot calculate the excess risk attributable to treatment. A 30-week follow-up is also too short and too small to settle uncommon or delayed risks.

Retention is part of the result. Forty-seven of the 268 baseline participants had either discontinued treatment or an unknown treatment status by the end. The authors identify out-of-pocket cost and adjustment during early dose escalation as real-world barriers, while also noting that missing data and discontinuation can bias an observational estimate^[2]. Anyone weighing treatment should use authorized product information and discuss costs and safety with a qualified clinician. The semaglutide safety summary covers the wider evidence base.

What we don't yet know

The largest limitation is the absence of randomization and a comparison group. Changes in other medicines, diet, activity, clinic contact, or regression to the mean could have contributed to the observed improvement. Recruitment from specialist urban centres also means the cohort may have had better access to monitoring than people receiving care in rural or less-resourced settings. Follow-up ended at 30 weeks, so durability beyond the early maintenance period remains unknown^[2].

BF BioSciences funded the study through an unrestricted grant. The authors state that the company supported coordination, site engagement, and data collection but had no role in study design, analysis, interpretation, manuscript preparation, or the publication decision. One author reported honoraria for educational lectures from the company^[2]. Those disclosures do not invalidate the findings, but they belong beside the efficacy numbers. A longer controlled study across a broader range of Pakistani clinics would provide firmer comparative evidence and a better account of retention and safety.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.